Trial 9L-17-4


Multicenter phase 1/2 Study of Combination Therapy with the DNA Methyltransferase Inhibitor Decitabine and the poly ADP ribose polymerase (PARP) inhibitor talazoparib (BMN 673) for untreated acute myeloid leukemia (AML) in adult patients unfit for cytotoxic chemotherapy or relapsed/refractory AML

Type: Treatment
Phase: Phase I/II
Status: Not Open (Closed)
Treatments: Other
Randomized: No
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Casey O'Connell, M.D.
Other Trial Staff:  Simbiso Peresuh, Coordinator, Christine Duran, D.M., Ibrahim Syed, D.M., Donna Fernando, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.